Hamish D. Toop
YOU?
Author Swipe
View article: Insights into the Interaction between Immobilized Biocatalysts and Metal–Organic Frameworks: A Case Study of PCN-333
Insights into the Interaction between Immobilized Biocatalysts and Metal–Organic Frameworks: A Case Study of PCN-333 Open
The immobilization of enzymes in metal-organic frameworks (MOFs) with preserved biofunctionality paves a promising way to solve problems regarding the stability and reusability of enzymes. However, the rational design of MOF-based biocompo…
View article: SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 Open
We recently identified the splicing kinase gene SRPK1 as a genetic vulnerability of acute myeloid leukemia (AML). Here, we show that genetic or pharmacological inhibition of SRPK1 leads to cell cycle arrest, leukemic cell differentiation a…
View article: Concise Total Synthesis of Dioncophylline E through an <i>ortho</i>‐Arylation Strategy
Concise Total Synthesis of Dioncophylline E through an <i>ortho</i>‐Arylation Strategy Open
The first total synthesis of the potent antimalarial 7,3′‐linked naphthylisoquinoline alkaloid dioncophylline E ( 1 ) has been completed. The synthesis proceeds in 12 steps (longest linear sequence) and in 15 % overall yield. Key transform…
View article: Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease Open
Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency an…
View article: Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors Open
Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibi…